Alfonso Quintás Cardama M.D.
Net Worth
Last updated:
What is Alfonso Quintás Cardama M.D. net worth?
The estimated net worth of Dr. Alfonso Quintás Cardama M.D. is at least $2,754,668 as of 13 Dec 2022. He has earned $40,348 from insider trading and has received compensation worth at least $2,714,320 in TCR2 Therapeutics Inc..
What is the salary of Alfonso Quintás Cardama M.D.?
Dr. Alfonso Quintás Cardama M.D. salary is $678,580 per year as Chief Medical Officer in TCR2 Therapeutics Inc..
How old is Alfonso Quintás Cardama M.D.?
Dr. Alfonso Quintás Cardama M.D. is 54 years old, born in 1971.
What stocks does Alfonso Quintás Cardama M.D. currently own?
As insider, Dr. Alfonso Quintás Cardama M.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| TCR2 Therapeutics Inc. (TCRR) | Chief Medical Officer | 109,459 | $0 | $0 |
What does TCR2 Therapeutics Inc. do?
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Alfonso Quintás Cardama M.D. insider trading
TCR2 Therapeutics Inc.
Dr. Alfonso Quintás Cardama M.D. has made 8 insider trades between 2021-2022, according to the Form 4 filled with the SEC. Most recently he sold 4,752 units of TCRR stock worth $5,042 on 13 Dec 2022.
The largest trade he's ever made was exercising 95,385 units of TCRR stock on 1 Dec 2022. As of 13 Dec 2022 he still owns at least 109,459 units of TCRR stock.
TCR2 Therapeutics key executives
TCR2 Therapeutics Inc. executives and other stock owners filed with the SEC:
- Dr. Alfonso Quintás Cardama M.D. (54) Chief Medical Officer
- Dr. Garry E. Menzel M.B.A., Ph.D. (61) Pres, Chief Executive Officer & Director